MarketCap
Facebook
X
TelegramAnnual report 2020
added 08-19-2023
ASLAN Pharmaceuticals Limited General and Administrative Expenses 2011-2025 | ASLN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.8 M | 7.17 M | 8.51 M | 10.5 M | 9.33 M | 6.92 M | 6.61 M | 2.82 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 M | 2.82 M | 7.96 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.28 | -2.28 % | $ 609 M |  Israel |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
22.2 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 94.73 | -1.32 % | $ 27.2 B | Germany |
 |
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
741 M | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
AstraZeneca PLC
AZN
|
15.2 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 9.09 | -0.55 % | $ 1.5 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 11.54 | 0.87 % | $ 746 M | USA |
 |
Biogen
BIIB
|
2.4 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
8.57 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Abeona Therapeutics
ABEO
|
19 M | $ 5.36 | -2.99 % | $ 115 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | $ 10.85 | -0.14 % | $ 1.41 B | USA |
 |
ADiTx Therapeutics
ADTX
|
16.3 M | $ 2.3 | -3.0 % | $ 30.3 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
19.7 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - | Russia |
 |
BioLineRx Ltd.
BLRX
|
4.31 M | $ 3.17 | -1.86 % | $ 908 M | Israel |
 |
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | USA |